NDC product
Ibuprofen and famotidine
NDC 67877-626 · Ascend Laboratories, LLC
Key facts
| Product NDC | 67877-626 |
|---|---|
| Proprietary name | Ibuprofen and famotidine |
| Nonproprietary name | Ibuprofen and famotidine |
| Substances | IBUPROFEN, FAMOTIDINE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Ascend Laboratories, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211890 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC], Nonsteroidal Anti-inflammatory Drug [EPC] |
| Marketing start | Aug 4, 2021 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: